Topical tranexamic acid effect on blood loss in hip fractured patients undergoing cemented bipolar hemiarthroplasty : A randomized controlled trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20201224005

Enrollment

Registered

2020-12-24

Start date

2017-06-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood loss Hemi hip replacement Tranexamic acid Blood loss

Interventions

&#45

1 g of TXA solution (20ml) was applied in to femoral canal and surgical field for 5 minutes then remove. &#45

1 g of TXA solution (20ml) was injected though the surgical field via suction drain tube.,&#45

0.9% NSS 20ml was applied in to femoral canal and surgical field for 5 minutes then remove. &#45

0.9% NSS 20ml was injected though the surgical field via suction drain tube.

Experimental Drug,Placebo Comparator Drug

Tranexamic,Normal saline

Eligibility

Sex/Gender

All

Age

60 Years to No maximum

Inclusion criteria

Inclusion criteria: Patient with femoral neck fracture Age > 60 year-old Schedule for Bipolar hemi hip arthroplasty

Exclusion criteria

Exclusion criteria: previous hip surgery pathological fracture allergic to tranexamic acid history of venous thromboembolism history of coagulation disorder history of hip infection.

Design outcomes

Primary

Measure	Time frame
Total blood loss 24 hour calculated from reduction of Hct at 24 hour	—

Secondary

Measure	Time frame
Complication (DVT, PE) 3 day Evaluated from clinical, ultrasonography and CT scan	—

Countries

Thailand

Contacts

Public ContactTheerawit Hongnaparak

Prince of Songkla University

theerawit.h@gmail.com074451601

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026